ELTX

Latest SEC Filings & News for ELTX

2 most recent filings and news items mentioning ELTX. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day

curl "https://api.brieftape.com/v1/tickers/ELTX/news?limit=20"

Pull ELTX filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day

RegulatoryJun 17, 2026Positive

Elicio Reports Complete Responses in Pancreatic Cancer Patients Receiving ELI-002 7P Plus Checkpoint Inhibition

Elicio Therapeutics reported that three metastatic pancreatic cancer patients achieved confirmed complete responses after receiving ELI-002 7P followed by nivolumab-based therapy, with responses persisting 8+ months. The company plans to initiate a Phase 1 study combining ELI-002

View filing at SEC.gov →

RegulatoryJun 15, 2026Negative

Elicio's ELI-002 7P misses Phase 2 primary endpoint but shows promise in R0 subset

Elicio Therapeutics reported that its AMPLIFY-7P Phase 2 study of ELI-002 7P failed to meet the primary disease-free survival endpoint in the intent-to-treat population for adjuvant pancreatic cancer, though post-hoc analysis showed benefit in completely resected (R0) patients re

View filing at SEC.gov →

AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.